Prevention of contrast-induced nephropathy and management of high-risk patients;La prevenzione della nefropatia da mezzo di contrasto e la gestione del paziente a rischio

Giornale Italiano di Cardiologia

Volumn 10, Issue 2, 2009, Pages 88-96

  Marenzi, Giancarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Contrast agents; Contrast induced nephropathy; Hemofiltration; N acetylcysteine; Renal failure; Renal prevention

Indexed keywords

AMINOPHYLLINE; AMLODIPINE; ASCORBIC ACID; CALCIUM ANTAGONIST; CAPTOPRIL; CONTRAST MEDIUM; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; MANNITOL; NIFEDIPINE; NITRENDIPINE; PROSTAGLANDIN E1; THEOPHYLLINE; TRIMETAZIDINE;

ANGIOGRAPHY; ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PREVENTIVE MEDICINE; PROGNOSIS; RADIODIAGNOSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 61849090479     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. US Renal Data System/National Institutes of Health. Annual data report: atlas of end-stage renal disease in the United States. http://www.usrds.org/adr.htm [accessed December 9, 2008].
2. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379-86.
3. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4 (Suppl 5): S3-S9.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
6. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.
7. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9.
8. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. Eur Radiol 1999; 9: 738-40.
9. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1780-5.
10. Becker CR, Davidson C, Lameire N, et al. High-risk situations and procedures. Am J Cardiol 2006; 98: 37K-41K.
11. Sisillo E, Ceriani R, Bortone F, et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 2008; 36: 81-6.
12. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983; 141: 1027-33.
13. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150: 1237-42.
14. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-9.
15. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention, Circulation 2002; 105: 2259-64.
16. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-6.
17. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 52: 409-16.
18. Briguori C, Marenzi G. Contrast-induced nephropaty: pharmacological prophylaxis. Kidney Int Suppl 2006; 69: S30-S38.
19. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron Clin Pract 2003; 93: C29-C34.
20. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36.
21. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-34.
22. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol 2006; 97: 981-3.
23. Maioli M, Toso A, Leoncini M. et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008; 52: 599-604.
24. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211-7.
25. Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol 2007; 49: 1283-8.
26. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007; 100: 781-6.
27. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-4.
28. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-8.
29. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-8.
30. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553-8.
31. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast-agent associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303.
32. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603.
33. Isenbarger D, Kent S, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 92: 1454-8.
34. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43: 1-9.
35. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15: 761-9.
36. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65: 1366-74.
37. Guru V, Fremes S. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004; 62: 77-83.
38. Bagshaw S, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2004; 2: 38.
39. Misra D, Leibowitz K, Gowda R, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 2004; 27: 607-10.
40. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004; 117: 938-47.
41. Liu R, Nair D, Ix J, Moore D, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005; 20: 193-200.
42. Duong MH, MacKenzie TA, Malenka DJ. N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005; 64: 471-9.
43. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 1799-806.
44. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006; 166: 161-6.
45. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41: 2114-8.
46. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25: 206-11.
47. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-82.
48. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837-42.
49. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93: 698-702.
50. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-9.
51. Moon SS, Bäck SE, Kurkus J, Nilsson-Ehle P. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Nephron 1995; 70: 430-7.
52. Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998; 13: 358-62.
53. Sterner G, Frennby B, Kurkus J, Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 2000; 34: 323-6.
54. Vogt B, Ferrari P, Schönholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111: 692-8.
55. Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007; 50: 1015-20.
56. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-40.
57. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119: 155-62.
58. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-28.